Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Home monitoring for hemophilia
February 2020
SHARING OPTIONS:

NIJMEGEN, The Netherlands—Enzyre and Takeda Pharmaceutical Co. Ltd. are working together under a research collaboration agreement to develop a diagnostic device for hemophilia patients to monitor their coagulation status at home. Per the agreement, Takeda will provide Enzyre with funding to allow the latter to further develop its technology. The goal is an option that will enable automatic determination of coagulation status and immediately transmit test results to a patient's physician via a mobile app.
 
“Diabetics have long been able to individually manage their disease through home glucose measurement, and we are determined to make this the case for those living with hemophilia,” stated Dirk Pollet, CEO of Enzyre. “With our proprietary technology, we aim to provide hemophilia patients and their caregivers with peace of mind by allowing them to monitor coagulation status at home. Ultimately, we'd like to empower these patients to live a normal life.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.